Verified American Company Independently reviewed and approved · June 2026

Edwards Lifesciences Corp

$85.98 -1.78% NYSE: EW · 15-min delayed

IRVINE, California
Public · NYSE: EW
16,000 employees

Visit website Follow

$49.5BMarket cap

$6.1BRevenue · FY2025

$1.1BNet income

16,000Employees

EWNYSE

2000IPO

About Edwards Lifesciences Corp

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

American Credentials

Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →

Company facts

Type: Public · NYSE: EW
Employees: 16,000
IPO date: Apr 3, 2000
Headquarters: ONE EDWARDS WAY
IRVINE, California 92614
Phone: (949) 250-2500
Industry: Medical Devices
Website: Visit site

Registry IDs

Ticker: EW NYSE
SEC CIK: 1099800
EIN: 364316614
SIC: 3842 ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow Edwards Lifesciences Corp and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $6.1B
Net income: $1.1B
Total assets: $13.7B
Market cap: $49.5B
Gross margin: 78.0%
Operating margin: 20.8%
Net margin: 17.6%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

FY2020

FY2021

FY2022

FY2023

FY2025

Revenue Net income

FY 2025

Financial statements

Income statement

Revenue: $6.1B
Cost of revenue: $1.3B
Gross profit: $4.7B
Operating expenses: $3.5B
Operating income: $1.3B
Income tax: $216.9M
Net income: $1.1B
EPS (basic): $1.84
EPS (diluted): $1.83

Balance sheet

Total assets: $13.7B
Current assets: $6.7B
Total liabilities: $3.4B
Current liabilities: $1.8B
Shareholders’ equity: $10.3B

Cash flow

Operating cash flow: $1.6B
Investing cash flow: -$712.9M
Financing cash flow: -$956.8M
Net cash flow: -$119.3M

Statements via Polygon.io (SEC filings)

NYSE: EW

$85.98 -1.78%

15-minute delayed · data by Polygon.io

Past year

$72.65 $88.16

52-week range

Market cap: $49.5B
P/E ratio: 47.0
EPS (diluted): $1.83
Shares outstanding: 575.7M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Apr 3, 2000

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

Profitable — net income of $1.1B in FY2025.
Revenue grew 38% from FY2020 to FY2025.
Gross margin of 78.0%, net margin 17.6%.
Trading near its 52-week high.
Valued at a price-to-earnings (P/E) ratio of 47.0.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.